Last reviewed · How we verify
HDM SLIT-tablet (12 SQ-HDM)
HDM SLIT-tablet delivers house dust mite allergen extract sublingually to induce immune tolerance through oral mucosal sensitization.
HDM SLIT-tablet delivers house dust mite allergen extract sublingually to induce immune tolerance through oral mucosal sensitization. Used for House dust mite allergic rhinitis and/or asthma.
At a glance
| Generic name | HDM SLIT-tablet (12 SQ-HDM) |
|---|---|
| Sponsor | ALK-Abelló A/S |
| Drug class | Sublingual immunotherapy (SLIT) tablet |
| Modality | Biologic |
| Therapeutic area | Immunology / Allergy |
| Phase | Phase 3 |
Mechanism of action
This sublingual immunotherapy (SLIT) tablet contains standardized house dust mite (HDM) allergen extract that is placed under the tongue, allowing the oral mucosa to present the allergen to immune cells and gradually shift the immune response from allergic (Th2) to tolerant (Treg-mediated). Repeated exposure to small, escalating doses of HDM allergen via this route desensitizes the immune system, reducing allergic symptoms upon natural exposure to house dust mites.
Approved indications
- House dust mite allergic rhinitis and/or asthma
Common side effects
- Oral pruritus / itching
- Throat irritation
- Mouth edema
- Gastrointestinal symptoms
Key clinical trials
- A Research Study of House Dust Mite (HDM) SLIT-tablet for the Treatment of HDM Allergy in Chinese Participants Aged 12-65 (PHASE3)
- Evaluate Measurement Instruments Relevance in Assessing Effectiveness of ACARIZAX® in House Dust Mite Allergic Rhinitis
- A Research Study in Chinese People With Allergy to House Dust Mites, Using an Environmental Exposure Chamber (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HDM SLIT-tablet (12 SQ-HDM) CI brief — competitive landscape report
- HDM SLIT-tablet (12 SQ-HDM) updates RSS · CI watch RSS
- ALK-Abelló A/S portfolio CI